To investigate whether the nuclear translocation of CD26 suppresses POLR2A expression, we first evaluated POLR2A expression in cancer cells after YS110 treatment, as YS110 induced the nuclear localization of CD26 (Fig. 2C). Here, POLR2A is linked to cancer.